Logo wahanariau.com
  2. Moonlake immunotherapeutics

Moonlake immunotherapeutics

Index
Globenewswire

MoonLake Immunotherapeutics Announces Landmark Phase 2 Results for Nanobody® Sonelokimab in Active Psoriatic Arthritis

Ahad, 05 November 2023 - 22:00:00 Wib
Globenewswire

MoonLake Immunotherapeutics Announces the full Dataset from its 24-week MIRA Clinical Trial, Establishing the Nanobody® Sonelokimab as a Highly Promising and Differentiated Therapeutic Solution for Hidradenitis Suppurativa

Ahad, 15 Oktober 2023 - 22:00:00 Wib
Globenewswire

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

Rabu, 28 Juni 2023 - 22:00:00 Wib
Globenewswire

MoonLake Immunotherapeutics Achieves Landmark Milestone with Positive Phase 2 Results for Nanobody® Sonelokimab in Hidradenitis Suppurativa

Ahad, 25 Juni 2023 - 22:00:00 Wib